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-COMMISSION OF THE  EUROPEAN COMMUNITIES 
Brussels,  14. 07. 1997 
CC )M(97) .162  finul 
Homeopathic l\ledicinal Products 
Commission Report to the European P"rliament and Council on the 
Application of DirecHves 92173- and 92174 .Homeopathic Medicinal Products· 
Commission Report to the European Parliament and Council on the 
Application of Directives 92i731 and 92/742 
!.Background: 
Over the past 30-40 years homeopathy has benefited- from  growing demand  both from 
doctors and· from the public in the majority of European countries. Three Europeans out 
of four  know  about· homeopathy  and  of. these  29% ·use  it  for  their  health  care  . 
. Ho.meopathi9 m-edicinal  products today account for a little over 1% of the gross sales of 
the European pharmaceutical  industry.  In Fnince,  Germany  and  The  Netherlands  this 
. 'figure is over 2% in value arid 5% by volume. 
In  1992  the  Council  adopted  Directives  92/73
1  and  92/74
2  on  homeopathic  medicinal 
products.  There were several  reasons  for  creating  specific  provisions for  homeopathic 
medicinal products:· Homeopathic medicine was officially  re~ognized i_n  certain  Member 
States but was only  toierated  in  other Member States.  Even  if homeopathic  medicinal 
products were not  al:Ways  officially  recognized,  they  were  nevertheless :prescribed  and 
·used in all  Member States. Considerable differenc,es in the status of alternative medicines 
-hindered  trade in  homeopathic  medicinal'  products within  the  Community  and  lead  to 
discrimination  and  distortion of competition between manufacturers of these  products. 
Moreover,  taking  account  of the  particular  characteristics  of homeopathic  medicinal 
products,. such as .the very low level of active principles they contain anq the difficulty of 
applying· to  them  the  conventional.  statistical  methods  relating  to  clinical  trials,  the 
regulatory framework  for  medicimil  products (in  particular the  pr(Jvisions  of Directive 
·  ·. 65/65/EECJ  and  Directive  75/319/EEC4)  seemed  to  be_  not  always  appropriate  for 
homeopathic medicinal products.  · 
·Council Directive 92173/EEC of 22  September  1992  widening the scope of Directives 65/65/EEC 
and 75/319/EEC on the approximation of provisions laid down by law,  regulation or administr;stive 
action  relating  to  mcdicinai  pr~ducts and . laying  down  additional  provisions  on  homeopathic 
medicinal products, OJ. L297, 13/10/1992  p.  8 
2  Council Directive 92174/EEC of22 September 1992 \Vi.dening the scope of Directive 81/851/EEC on 
the approximation of provisions laid down by  law,  regtila'tion  or administr:ative action relating to 
veterinary· medicinal  products  and  laying  down  additionpl  provisions  on  homeopathic veterinary 
medicinal products, OJ. L297;13/l011992 p.  1.2 
3  ·  Coundl Directive 65/65/EEC of 26 January  1965  on the approximation of provisions laid down  by 
law,'  regulation 'or  administrative  action  relating  to  proprietary  medicinal  products,  01.22, 
09/02/1965 p. 369  .  . 
4  . Council Directive 75/319/EEC of 20 May I  ~)75 on the  approxim~tion of pro,:isions  laid  down by 
law, regulation or admin-istrative action relating medicinal products,-OJ. Ll.J7 , 09/06/llJ7 5 p.  l3 
1 By means ofDirectiv~s 92/73 and 92/74 it was intended to create a legal frame that would 
allow patients access to the medicinal products of.their choice provided all precautions are 
taken to ensure the quality  and  safety of the  said  products;  to  provide  users of these 
medicinal products with a very clear indication of their honieqpathic ·character and with 
sufficient guarantees of their quality and safety and to harmonize the rules relating to the 
manufacture,  control  and  inspection of h9meopathic  medicinal  products  to  permit  the  ·  ~ 
circulation throughout the Community of medicinal products which are safe and of good 
quality. 
To this end, Directives 92/73 and 92/74 provided for the creation of a special, simplified 
registration  procedure  in  Member  States  for  those  traditional  homeopathic  medicinal 
products  which  are  placed  on  the  market  without  therapeutic  indications  in  a 
pharmaceutical form and dosage which do not present a risk for the patient.  Regarding 
homeopathic  medicinal  products with  therapeutic  indications  or in  a  form  which  may 
present risks,  the usual rules governing the authorization to market medicinal  products 
should be applied. Member States which had a homeopathic tradition should be, however, 
able to apply particular rules for the evaluation of  the. results of  tests and trials intended to 
establish· the safety and efficacy ofthese m_edicinal products  . 
. According to  Article  10  paragraph  3 ·of I;>irectives  92173  and  92174,  the  Commission 
should, not later than 31 December 1995, present a repof1 to the European Parliament and 
the Council concerning the application of the Directives.  Given that on 31st December 
1995, the date by which this report' should have been presented, not all  Member States 
had notified the Commission of the full  application of the Directives,  the  Commission 
decided to put back the completion of  the study until the end of 1996 in order to be able 
to  take  onboard  the  practical  experie-nces  in  some  Member  States  that  were  late  in 
transposing the Directives. As this report is drafted, (January 1997) most Member 'states 
have notified implementation of both Directives, Infringement procedures concerning full 
or partial non-transposition had to be started (and are still  under way)  againstBelgium 
and  France  regarding  Directiv~ 92173  and  against  Belgium,  France,  Portugal  and  the 
United Kingdom regarding Directive 92/74. 
The analysis which follows is based on an  ·in-depth study on the application of  Directives 
92/73  and  92/74  performed  by_  independent  consultants  on  behalf of the  European 
Commission. It will show a certain degree of disparity in the application of  the DireCtives 
in  Member  States  and  contradictions  in  the  interpretation  thereof.  Therefore, · in  jts 
conclusion, this report will ask the European Council and Parliament to express their view  ' 
on particul·ar problems and to consider whether certain amendments would  help  to fully 
achieve the initial objectives. 
· 2.App1ication of Directive 92173 (homeopathies for human use): 
Definition of  homeopathic medicinal product:- . 
According  to  Article  I  of Directive. 92173  'homeopathic  medicinal product' shall 
mean any medicinal product prepared from produCts,  substances or compositions 
called  homeopathic  stocks  ill  accordance  with · a  homeopathic  manufacturing 
procedure described by the European Pharmacopoeia or,  in absence thereof,  by the 
pharmacopoeias  currently  used  officially  in  the  Member  States.  Homeopathic 
medicinal products may also contain a number of  principles. 
2 All· cou_!ltries  have accepted this definition· of homeopathic medicinal  product when 
transposing this Article. Ireland alone has not transposed paragraph 2 of Article 1 "A 
homeopiJthic  medicinal pr~duct may also  cont~in a  number  of prii;Cipies ";  The . 
status of a homeopathic medicinal  produc~ is  henceforth recognised throughout the 
Europe~m Union,  since  Member  States  have  adopted  and . accepted  an  identical 
definition.  Therefore  no  ne~d for  further  Community  action  with  regard  to  this 
. definition arises; 
'  . 
Manufacture. control and. inspection. information exchange: 
· Only some Member States have transposed the relevant Articles 3  '- ·  5 of Directive 
92173  with complete clarity. The absence of  transposition in other Member States can 
be  explained . on  the  basis .  ,of  the  application.  and  transposition  of  Directive 
75/319/EEC,  prior  to Directive  92173/EEC,-in  particular  chapters IV referring  to 
.manufacture  arid  imports  coming  from  third  countries  and  chapter  V  refering  to 
supervision and sanctions. Taking into account that no complaints or new suggestions 
with regard to these Articles have been .received by the- Commissic;m,  it, seems to be 
acceptable to leave these Articles as they are.  ' 
Placi~g  on  the ·market  of. homeopathic  medicin-al  products  - Registration  and 
Authorization:·  ·  · 
Article.  6  paragraph  1  of Directive  92173 · obliges  Member  States  to  ensure  that 
homeopathi-c medicinal products manufactured imd placed on the market within the 
Community  are ·registered  or  authorized  In  accordance  with  the  provisions· of 
Directive 92173.  Moreover it  is  foreseen  that  "Each Member State  shall take  due 
account of  registratiot1s and authorizations previously granted by another Member 
State."  ·  ·  · 
· All  countries  have  transposed  this  paragraph:  Henceforth  homeopathic  medicinal 
products put on the market in .the European Union must have either a registration or 
an  auth_orization.  How~ver,. the  interpretation of the  formulation  « Each  Member 
State shall take  due  account of  registrations and authorizations previously granted 
by another Member State» varies amotlg Member States: 
- Denmark interprets it very widely  on the basis of mutual  recognition,  a~cepting · 
without any  restriction homeopathic medicinal  products that have  already. obtained ' 
regi~traticin or authoriz~tion in another Member State.  . 
:-- Germany follows the Danish line, but does not accept mutu·al  recognition unless the 
product meets all  national criteria, for example being included in  traditional German 
·homeopathy. Consequently, .there Is no real mutual recognition. 
- Sweden takes account of  registrations and authorizations already granted and allows 
the submission of a· simplified  do~sier, provided the appiicant shows that the product 
submitted  for  registration  has  been _pres~nt on  the .market  for  at  least  ten years in 
another Member State.  .  .  .  . 
- For other countries,  registrations  and  authorizations  delivered  by  other Member 
States are 'only t.aken  into account when a registration is  submitted and  this is purely 
an  administrative  ·acknowledgement, ·  with'.  neither  . mutual  .-rec-ognition.  nor 
· simplification of  administrative procedures. 
According . to  manufacturers'  opinions  supported  by  consumers  .  and  doctors 
organisations,  the  wording  « shali take  due  account of registrations  ... » does not 
guarantee mutual recognition of registrations of homeopathic medicinal  products by 
other Member  States.  The  ~ording «take account  of»  is not  precise  enough to 
. impose a dear and  unambigous obligation on Member States.  As  a. result  it  would 
~  . 
3 induce a barrier to the Single Ma_rket  of homeopathic medicinal  products and  there 
:would be need for legislative activities on Community leveL 
Abstention from the introduction of  a simplified registration procedure): 
No Member State informed the Commission to make use of the possibility (provided 
for  in  Article  6  paragraph  2),  to  abstain  from  the  introduction  of a · simplified 
registration procedure. Therefore this provision is presently not applicable. 
Placing on the market - Advertising: 
Article 6  paragraph 3.  leaves Member States the choice of allowing advertising for 
homeopathic medicinal products subject to the provisions of  Directive 92/285 on the 
advertising  of.  med.icinal  products  and  some  special  conditions  stated  in  Article  6 
paragraph  3,  or  forbidding  all  advertising  for  the  above  mentioned  medicinal 
products. Three· countries (Austria,  Italy and Luxemburg) have chosen to forbid  all  . 
advertising. Five countries (France, Germany, the Netherlands, Spain and the United 
Kingdom) :allow advertising in  line with Article 6' paragraph 3.  Denmark authorizes 
advertising ·for the  medical  profession ·but  forbids· it  for  consumers  and  Belgium, 
Ireland, Portugal and  Sweden have  ~ot expiicitly transposed  this  article.  Since this 
article is optional, it is notsurprising to find that provisions differ from Member ·state 
to Member State.  Taking into· account that no  complaints or new suggestions with 
regard to this paragraph have been received ·by  the Commission, it  is  acceptable to 
leave the paragr(!.ph as it is.  ' 
Eligibility. for the simplified registration procedure: 
According to Article 7 paragraph 1 ·"only homeopathic medicinal products which satisfy 
all of the  following  conditions  may  be  subject  to  a  special,  simplified registration 
}  - . 
procedure: . 
- they are administered orally or externally,  _ 
- no specific therapeutic indication appears on the labelli11g of  the medicinal product or 
in any information relating thereto, 
- there is a sufficient degree of  dilution to guarantee the safety of  the medicinal product; 
in particular,  the  medicinal product may not contain  either more  than  one  part per 
10.000 (D4)  of  the  mother tincture or more than  1/100ih of the  smallest dose  used in 
allopathy with regard to  active principles whose presence  in  an  allopathic  medicinal 
product results in the obligation to submit a doctor's presc,ription." 
All Member States have paid attention to this article, but some of  them have laid out 
own dispositions concerning routes of  administration and registerable dilutions: Some 
countries ·(Denmark,  Finland,- Luxemburg,  the  Netherlands,  Portugal,  Spain  and 
Sweden)  have. transposed  the  article  as·  it  stands  but  others  have  introduced 
modifications or precisions: 
Modifications concerning the routes of  administration: 
In France,  homeopathic medicinal  products  adminis~ered qy  subcutaneous injection 
can  be  registered  according  to  specific  rules.  In  Italy  and  the  United .  Kingdom 
injections  are  explicitly  excluded.  Italy  goes  further,  also  ex:Cluding  transdermal 
s  Directive 92/28/EEC of 31  March 1992 on the advertising of medicinal products for  humim usc, OJ 
Ll13, 31/03/1992, p.l3 
4 .  .  .  '  .  .  . 
administration '(patches).  Although accepted for the simplified regrstration procedure 
in  some  other  Member  States,  in  Firiland  eye  drops  and  suppositories  must  be 
authorised according ~o the standard procedure. 
Modifications concerning registerable dilutions: 
In  Austria, .  only  substances  describe~ .  in ·a  pharmacopoeia  of the  ~EA  ·may  be 
. registered .and  a  list  pf substances  has  been  established  specifying  the  minimum 
registerable dilutions.  These di.Iutions go from Dl (1/10) to D8 (1/100.000.000).  In 
Germany,  ~he registerable dilution thresholds ·have been·  replac~d by  the requirement 
of "an absence of harmful effects". What is more, the registration of a ·homeopathic 
medicinal product can be refused i[  it does not meet all of the criteria defined by the.\ 
·German authorities  (ie:  being  generally  known  for  homeopathic  or antroposophic 
use).  The  United  Kingdom. and Ireland  have  fixed  the  dilution  threshold  to  D4 
· (1/10.000) for all products submitted to a simplified registration. 
.  . 
Even  though  the  European·  Commission  gave  an  interpretative  clarification 
concerning the registerable dilutions6,  it  is: npticeable that there is  a:  large degree of  . 
difference of interpretation between transpositi.ons  at· national  level. Thfs ·results  ir:t 
different systems of registration,  ~orne of which are· more open than the others and 
.~How the registration of  a greater range of  homeopathic medicinal products. 
Manufacturers, doctors. and consumers' agree; that if it was not possible to register 
mother tinctures  ·and  dilutions  between  Dl  (IiiO)  and  D4  (1110.000) dt  high 
percentage of single and complex homeopathic medicinal products would  ha~e to be 
withdrawn or have to-be changed, as one or more active ingredients are in a potency 
lower than D4 (1/10  .. 000).  The companies would have to create-new formulas  and  . 
start the· research at:td  development period from the begiimi~g concerning the clinicat' 
data and  the · empirical  knowledge  of  these -homeopathic . medicinal  products. · 
Therefore,  a clarification that the threshold ·of D4 !lPPiied  only to active  principles 
whose presence in an allopathic medicinal product results in the obligation to submit a 
doctor's prescription or a more flexible solution (like the Austrian approach with lists 
of registerable  substances)  is  asked  for.  Moreover it has to be stated  that  lack of 
harinonised· Community  lists  of. active  principles  whose  presence  i'n ·an aJiopathic 
medicinal product results in  the obligation to submit a doctor's prescription leads to 
disharmony in the application of  the present prc;>vision.  ·  ' 
Likewise  it · was  criticized  that· the · Directive  limits  the  simplified  registration 
procedure to. homeopathic medicinal  products whos'e  route of administration is  oral 
or ·-external.  According  to  some/ opinions  it  should  · be  applicable  to  other 
pharmaceutical  forms.  Thus  such  routes  of  administration  as  subcutaneou-s  · 
administration, or  .nasal spray; should be r~gisterable under a simplified procedure. In  · 
this  context it  has. been  stressed that the  homeopathic industry states that  it. coul~ 
refer to a safe and  secure experience with a simplified registration for the parenteral 
pharmaceutical form.  Those who propose an  extension of the simplified  registration · 
procedure  "to other routes of administration stress in  particular the fact that Chapters -
IV  and  V  of  Di~ective ' 75/319  and  the  principles  and  guidelines  of  good 
manufacturing practice are fully applicaole to  all homeopathic medicinal products. 
6 sec: answer of the Commission to written question E-280-t/95, OJC66, 4.3.1996, p.31 
5 Labelling and package insert: · 
Article·? .paragraph 2 ofDirective.92173 states that in addition to the clear mention of 
the words  'homeopathic  medicinal  product',  the  labelling  and,  where  appropriate, 
package insert for homeopathies subject to a simplified registration shall bear certain 
specified,  and  no  other,  information (including the phrase  "homeopathic medicinal 
product without approved therapeutic indication"). 
Most Member States have transposed this Article without modification.  Some have, 
howe:ver, slightly divergent provisions in their national transposition. So, in Denmark,  .  . 
the clause "homeopathic medicinal product without approved therapeutic indication 
is replaced by "Homeopathic medicinal product, whose efficacy is  not documented", 
in Finland, this clause is  not mentioned  in  the regulations for labelling,  in  Germany, 
. the term "approved" does not appear and.  in  the Netherlands,  the applicant  has the 
choice between the terms "approved" and "specific". In addition, the requirement of 
including the registration.number is absent from the labelling regulations in Denmark. 
Manufacturers,  doctors and  consumers criticize that the Directive excludes fantasy 
names  for  preparations  combining  a  number  of substances.  Inclusion  of all  the 
scientific names on the label of  a preparation would make an identification difficult if 
not" impossible. It  was also pointed out that the Directive specified the inclusion of  the 
method of  administration on the labelling and package insert and that this should also 
include the dosage  ~here appropriate.  The clause "without therapeutic  indication" 
was criticized for being misleading and was generally seen as the most controversial 
issue in the context oflabelling ofhomeopathics. 
Content of  the application dossier for a simplified registration 
Article 8 of  Directive 92/73 outlines the documents that have to be included with the 
application for a simplified registration. Most countries have correctly transposed this 
Article.  However,  two  Member  States,  France  and  Ireland,  have  stricter 
interpretations of the Directive:  In France, the documents to be supplied  are more 
numerous  and  the  registration  dossier  is  closer  to  a  standard  application  for  a . · 
marketing  authorization.  The  "usual  denomination"  can  be  used  for  registration 
purposes.  Homeopathic  medicinal  products  other than  those  intended  for  oral  or 
external  use,  in  particular  subcutaneous  injectables,  can  be  r~gistered  through  a 
separate-application that justifies the necessity of using the routes of administration 
concerned. In Ireland, supplementary requirements concerning the· person responsible 
for placing the product on the market and the manufacturer, whose identity must be 
clearly discen1ibl~. have been established. 
Apart from  current French legislation according to which the simplified  registration 
· dossier is  close to a standard application dossier for authorization, the transposition 
ofthisArticle poses no particular problems. 
Marketing authorization and specific rules for homeopathic medicin~ll products: 
According  to  Article  9  6f Directive  92173,  homeopathic' medicinal  products  not 
subject to the  simplified  registration  procedur~ shall· be  authorized  and  labelled  in 
accordance  with  Directive  65/65  including  the  provisions  concerning  proof of 
therapeutic  effect.  However,  Article  9  paragraph  2  gives  Member  States  the 
possibility.  to  introduce  or  retain·  in  their  territory  specific  rules  for  the 
pharmacological  and  toxicological  tests  and  clinical  trials  in  accordance  with  the  .  . 
6 principles  and  characteristics  of homeopathy  as  practised  in  that  Member  State. 
Austria, France and the Netherlands accordingly provide fofspecific rules which take 
'account  of the  character of homeopathic  medicinal  products  and  their  traditional 
. forms of use;  Germany  has. established  monographs  and  elaborated  guidelines  for 
clinical· tests which are equally valid for homeopathic medicinal  p_roducts  subject,  t~ 
registration; Italy has created a commission charged with defining specific  n'?~ms for 
the authorization and labelling of homeopathic medicinal products other than those . 
covered by Article 7 paragraph -1  of  the Directive; Spain mentions in its transposition 
that "account will be taken of the homeopathic nature of medicinal products during 
the·  ~valuation of  the' tests':.  Other Member States have not specifically  transposed 
this Article. ·  ~  ·  · 
It ·  se~ms that  some  countries  have  not  transposed.  this  Article  because  general 
regulations already included homeopathic medicinal products subject to authorization. 
As the introduction of specific rules. is  not obligatory, most Member States .have not 
taken clear action.  Only Germany has clearly defined these rules, because of its own. 
}:lomeopathic tradition._ France and Spain ·remain vague and Italy and the-Netherlands· 
have still not named a commissio'n charged with developing these rules.  . 
.  ~  t  . 
Manufacturers ·~re 'concerned that Article 9 is  optional and  not binding on Member 
- States  and  that  the  formulation  in  Article  9  paragraph 2  "specific  rules  ....  in 
accordance with  the  characteristics of homeopathy  ... "  is  too  vague> Therefore  a 
Single Market for homeopathic medicinal products with therapeutic indicatipns would 
be impossible. They have asked that it should be clearly stated that-these specific rules 
should provide· for  the  involvement  of -·appropriate  experts  in  homeopathic  and 
.. anthroposophic medicine  and  that  Article  9  paragraph  2  should become  a  binding 
.provision  .. 
. -
3.Application of  Directive 92174 (homeopathies for veterinary use): 
The stnictu;e and  wording of Directive 92174  on homeopathic veterinary medicinal 
products is nearly identical to the text of  Directive 92173  on homeopathies for. human 
use.  Therefore it  is  no  surprise that the  problems  and  results ·outlined  above  with 
regard to homeopathies for human use can be - mutatis mutandis - fully applied to the 
application.ofDinictive 92174 on homeopathic veterinary medicinal products  . 
. There is,  however,  one specific  requirement coocerning the eligibility  for  the  simplified · 
registration  procedure .of  homeopathic  medicinal  products  for: veterinary  use  that  has 
given rise to criticism from  interested  parties:  Article 7  paragraph  I  of Directive 92/74 
requires ·that the  products· eligible  for· the  simplified  registration -"are  intended for 
administrqtion to petaninwls or exotic species whose flesh or products are not inte1ided 
. for human consumption" and ther.eby  exclude's  the simplified  registration procedure for 
homeopathics}ntended ·to be administered to food producing animals.  ·  · 
7 4. Conclusions: 
It has been shown that starting from regulatory texts whose objectives were very clearly. · ' 
. expressed in 1992- to achieve the harmonisation of  regulations for homeopathic medicinal· 
products and  enable their free· circulation  - a  certain but  not. yet  satisfying  degree  of 
harmonisation has been achieved in  1997.  · 
Following practical experience with the implementation of  Directives 92/73 and 92/74, the 
enlargment of the  EU  and  change~ in  opinions  within  Member  States,  Council  and 
Parliament may have different views on certain points today from the positions taken in 
199f. Before presenting any concrete proposal for an amendment to Directives 92/73 and 
92/74 and in order to determine feasible solutions to the problems raised in this report, the 
European Commission invites the European Parliament and Council to express their views 
and positions on the following suggestions in their response to this report:  · 
•  The wording of Article  6  paragraph  1 (of Directives  92)73  and  92/74)  "Each 
Member· State  shall  take  due  account  of registrations  and  authorizations 
previously granted by another Member Sta1es"  could be reconsidered in order to 
to define· exactly  under which specific  conditions  existing  national  registrations 
should  be mutually recognised or endorsed by other ~ember  States. 
•  Article 7 paragraph 1 of  Directive 92/73 could be amend~d in order to increase the  ' 
scope of products subject to a simplified registration procedure. In  particular this 
could  involve  the  explicit  inclusion  of  other  routes  of  administration  and 
modifications/clarification concerning registerable· dilutions. 
•  Article 7 paragraph 1 of Directive 92/74 could be amended in  order to make the 
simplified  registration  procedure also  applicable to homeopathies intended  to be 
administered to food producing animals, whilst taking into account the importance 
of  maintaining stringent measures to protect consumers in this sensitive area. 
•  Article 7 paragraph 2 .of Directive 92/73 and 92/74 could be amended to allow for 
the use of fantasy names for combination preparations.  The information  required 
on the labelling:  "homeopathic medicinal product 'without  approved therapeutic 
indication"  could  be  changed  into  "homeopathic ·medicinal product  without 
medical claim".  A possibility to include the normal daily  dosage in  the labelling 
and  a  revision  of the warning  to  consult  a  doctor· to  make  the  labelling  more 
. consumer friendly could as well be considered.  . 
•  With regard  to Article  9  paragraph 2 of Directives 92/7J and  92/74  (tests and 
clinical trials) it could be considered to make this provision ·binding and to demand 
explicitly  that the "specific  rules  for  tests and  clinical  trials  in  Member  States" 
should  provide  for  the  involvement  of appropriate  experts  in  homeopathic  and 
anthroposophic medicine.  · 
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